Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis

Paul J. Pockros, Lennox Jeffers, Nezam Afdhal, Zachary D. Goodman, David Nelson, Robert G. Gish, K. Rajender Reddy, Robert Reindollar, Maribel Rodriguez-Torres, Sarah Sullivan, Lawrence M. Blatt, Sima Faris-Young

Research output: Contribution to journalArticle

89 Scopus citations

Abstract

Interferon-γ1b (IFN-γ1b) is a pleiotropic cytokine that displays antifibrotic, antiviral, and antiproliferative activity. A total of 502 patients with compensated liver disease and an Ishak fibrosis score of 4-6 were randomized in a double-blind, placebo-controlled study, and 488 of these patients received subcutaneous injections of IFN-γ1b 100 μg (group 1, n = 169), IFN-γ1b 200 μg (group 2, n = 157), or placebo (group 3, n = 162) 3 times a week for 48 weeks. Most patients (83.6%) had cirrhosis at baseline (Ishak score = 5 or 6). Posttreatment liver biopsies were assessed in a blinded fashion for a reduction of 1 or more Ishak points (primary endpoint). Four hundred twenty patients with pretreatment and posttreatment liver biopsies were evaluable and showed no improvement in Ishak score between the 3 treatment groups (12.1%, 12.4%, and 16% of patients in groups 1, 2, and 3, respectively; P > 0.05). Analysis of IFN-γ-inducible biomarkers revealed that interferon-inducible T cell-alpha chemoattractant (ITAC), an IFN-γ-inducible CXCR3 chemokine was an independent predictor of stable or improving Ishak score. IFN-γ1b was well tolerated. There were similar numbers of deaths in all 3 arms (5, 5, and 4, respectively), and most were related to complications of cirrhosis. Conclusion: IFN-γ1b therapy was not able to reverse fibrosis in patients with advanced liver disease for 1 year. Subgroups of patients with elevated ITAC levels and perhaps less advanced disease may be considered for future studies with IFN-γ1b.

Original languageEnglish (US)
Pages (from-to)569-578
Number of pages10
JournalHepatology
Volume45
Issue number3
DOIs
StatePublished - Mar 1 2007

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis'. Together they form a unique fingerprint.

  • Cite this

    Pockros, P. J., Jeffers, L., Afdhal, N., Goodman, Z. D., Nelson, D., Gish, R. G., Reddy, K. R., Reindollar, R., Rodriguez-Torres, M., Sullivan, S., Blatt, L. M., & Faris-Young, S. (2007). Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology, 45(3), 569-578. https://doi.org/10.1002/hep.21561